121495-40-7

Usage

Chemical Family

isoindole-1,3-dione

Structure

contains a BOC protecting group on the N-methylaminoethyl group

Use

useful intermediate in organic synthesis

Potential Applications

medicinal chemistry and pharmaceutical research

Reason for Applications

identified as a pharmacophore in various bioactive molecules

Stability

increased stability due to the presence of the BOC protecting group

Controlled Release

allows for the controlled release of the N-methylaminoethyl group under specific conditions

Value in Drug Development

a valuable tool in drug development and chemical biology studies

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 56686-38-5 2-(2-(methylamino)ethyl)isoindoline-1,3-dione 
• 77361-32-1 N-(2-tert-butoxycarbonylaminoethyl)phthalimide 
• 74-88-4 methyl iodide 
• 524-38-9 N-hydroxyphthalimide 
• 121492-06-6 (2-aminoethyl)methylcarbamic acid tert-butyl ester 
• 85-44-9 phthalic anhydride 
• 603-35-0 triphenylphosphine 
• 136918-14-4 phthalimide 
• 57561-39-4 methyl(2-hydroxyethyl)carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION

The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are bicyclic compounds that are inhibitors of PD-1/PD-L1 interaction/activation.

COMPOUNDS AND METHODS

Disclosed are compounds having formula I, wherein X1, X2, X3, R1, R2, R3, R4, R5, Y, A, Z, L, m and n are as defined herein, and methods of making and using the same.

MELANOCORTIN RECEPTOR AGONISTS

The present invention relates a compound of formula 1, and pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.

Pyridinium derivatives, their production and use

Novel pyridinium derivatives represented by the formula (I): STR1 wherein STR2 is an optionally substituted pyridinium ring; R1 is a lower alkyl group or aralkyl group; R7 and R10 are independently hydrogen, a lower alkyl group, aryl group or aralkyl group; l is 0 or 1; R5 is a phenylene group or an alkylene group which may be substituted; R11 is an alkyl group or aryl group; X is a group of the formula: --CH2 OCH2 -- or a group of the formula: STR3 wherein R6 is hydrogen, a lower alkyl or a lower alkoxy, and m is an integer of 0 to 3; U is a group of the formula: STR4 wherein R4 is hydrogen, a lower alkyl group, aryl group or aralkyl group; Y and Z are independently a divalent chain group consisting of one to six members which is selected from the class consisting of groups of the formulae: STR5 wherein R is hydrogen, a lower alkyl group, acyl group or aryl group and at least one of which is a group of the formula: STR6 with the proviso that R may be the same or different from each other, or may form a ring together when two or more groups of the formula: STR7 are present, that R may be bonded to R4 when Y contains a group of the formula: STR8 and that R may be bonded to R11 when Z contains a group of the formula: STR9 and W? is a counter anion; are useful as a platelet activating factor antagonist.